#METABOLOMICS WORKBENCH RMbeach1053_20221121_093934 DATATRACK_ID:3589 STUDY_ID:ST002354 ANALYSIS_ID:AN003843 PROJECT_ID:PR001511 VERSION 1 CREATED_ON November 22, 2022, 5:53 am #PROJECT PR:PROJECT_TITLE Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. PR:PROJECT_SUMMARY Comprehensive analysis of the lipidomic changes resulting from feeding with a PR:PROJECT_SUMMARY over EPA analogue alone, and in combination with the NSAID naproxen. PR:INSTITUTE UConn Health PR:DEPARTMENT Center for Molecular Oncology PR:LABORATORY Rosenberg Laboratory PR:LAST_NAME Beach PR:FIRST_NAME Ryan PR:ADDRESS 263 Farmington Avenue, Farmington, Connecticut, 06030, USA PR:EMAIL rbeach@uchc.edu PR:PHONE 860-679-8703 PR:FUNDING_SOURCE NCI PREVENT funding #STUDY ST:STUDY_TITLE Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. ST:STUDY_SUMMARY Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in ST:STUDY_SUMMARY the United States. Patients with the genetic disorder Familial Adenomatous ST:STUDY_SUMMARY Polyposis (FAP) develop hundreds to thousands of polyps that unless removed by ST:STUDY_SUMMARY prophylactic colectomy will progress to CRC at an early age. Non-steroidal ST:STUDY_SUMMARY anti-inflammatory drugs (NSAIDs) and -3 marine polyunsaturated fatty acids ST:STUDY_SUMMARY (PUFA), such as eicosapentaenoic acid (EPA), have been evaluated for their ST:STUDY_SUMMARY chemopreventive potential in delaying the onset of CRC in high-risk patients. In ST:STUDY_SUMMARY this study, we determined whether the NSAID, naproxen, alone or in combination ST:STUDY_SUMMARY with a chemically-stable form of EPA (TP-252), affects tumor formation in the ST:STUDY_SUMMARY ApcPirc rat model. When compared to control diet, animals fed naproxen or HD ST:STUDY_SUMMARY TP-252 had 66%, and 82% fewer tumors respectively. However, when fed a ST:STUDY_SUMMARY combination of naproxen and HD TP-252, animals exhibited a 95% reduction in ST:STUDY_SUMMARY tumor formation and a 98% reduction in tumor volume, respectively. To elucidate ST:STUDY_SUMMARY potential mechanisms of tumor protection, a comprehensive, targeted lipidomic ST:STUDY_SUMMARY analysis was performed on colonic mucosa to determine changes in eicosanoid ST:STUDY_SUMMARY metabolism. Animals receiving TP-252 alone or in combination with naproxen had ST:STUDY_SUMMARY significantly reduced mucosal levels of pro-inflammatory -6 eicosanoids ST:STUDY_SUMMARY (PGE2, 5-HETE, and 14,15-DiHETrE), along with a simultaneous increase in ST:STUDY_SUMMARY anti-inflammatory EPA-derived -3 eicosanoids. Our colonic mucosal lipidomic ST:STUDY_SUMMARY analysis also uncovered several potential pharmacodynamic (PD) lipid biomarkers, ST:STUDY_SUMMARY including resolvin E2, 9-HEPE, 12-HEPE and 18-HEPE, that were increased in both ST:STUDY_SUMMARY the tissue and plasma of rats receiving TP-252 and were significantly correlated ST:STUDY_SUMMARY with tumor protection. Further studies with this drug combination should be ST:STUDY_SUMMARY focused on dose optimization and the role of EPA-derived lipid mediators in CRC ST:STUDY_SUMMARY initiation and progression. ST:INSTITUTE UConn Health ST:LAST_NAME Beach ST:FIRST_NAME Ryan ST:ADDRESS 263 Farmington Avenue, Farmington CT 06030 ST:EMAIL rbeach@uchc.edu ST:PHONE 860-679-8703 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Rattus norvegicus SU:TAXONOMY_ID 10116 SU:AGE_OR_AGE_RANGE 26 weeks of age SU:WEIGHT_OR_WEIGHT_RANGE 320-460 grams SU:GENDER Male SU:ANIMAL_ANIMAL_SUPPLIER RRRC (University of Missouri) SU:ANIMAL_HOUSING Center for Comparative Medicine UConn SU:ANIMAL_FEED Modified AIN-93G diet from Research Diets SU:ANIMAL_WATER ab libitum #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS 2440 TFA-T1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T1.wiff SUBJECT_SAMPLE_FACTORS 2443 TFA-T2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T2.wiff SUBJECT_SAMPLE_FACTORS 2538 TFA-T3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T3.wiff SUBJECT_SAMPLE_FACTORS 2547 TFA-T4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T4.wiff SUBJECT_SAMPLE_FACTORS 3181 TFA-T5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T5.wiff SUBJECT_SAMPLE_FACTORS 3183 TFA-T6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T6.wiff SUBJECT_SAMPLE_FACTORS 2444 TFA-T7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T7.wiff SUBJECT_SAMPLE_FACTORS 2445 TFA-T8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T8.wiff SUBJECT_SAMPLE_FACTORS 2446 TFA-T9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T9.wiff SUBJECT_SAMPLE_FACTORS 2336 TFA-T10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T10.wiff SUBJECT_SAMPLE_FACTORS 2850 TFA-T11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T11.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-T12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T12.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-T13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T13.wiff SUBJECT_SAMPLE_FACTORS 3099 TFA-T14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T14.wiff SUBJECT_SAMPLE_FACTORS 2448 TFA-T15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T15.wiff SUBJECT_SAMPLE_FACTORS 2449 TFA-T16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T16.wiff SUBJECT_SAMPLE_FACTORS 2450 TFA-T17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T17.wiff SUBJECT_SAMPLE_FACTORS 2901 TFA-T18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T18.wiff SUBJECT_SAMPLE_FACTORS 2903 TFA-T19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T19.wiff SUBJECT_SAMPLE_FACTORS 3020 TFA-T20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T20.wiff SUBJECT_SAMPLE_FACTORS 3021 TFA-T21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T21.wiff SUBJECT_SAMPLE_FACTORS 2451 TFA-T22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T22.wiff SUBJECT_SAMPLE_FACTORS 2453 TFA-T23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T23.wiff SUBJECT_SAMPLE_FACTORS 2454 TFA-T24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T24.wiff SUBJECT_SAMPLE_FACTORS 2884 TFA-T25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T25.wiff SUBJECT_SAMPLE_FACTORS 2885 TFA-T26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T26.wiff SUBJECT_SAMPLE_FACTORS 2271 TFA-T27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T27.wiff SUBJECT_SAMPLE_FACTORS 2282 TFA-T28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T28.wiff SUBJECT_SAMPLE_FACTORS 2344 TFA-T29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T29.wiff SUBJECT_SAMPLE_FACTORS 2458 TFA-T30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T30.wiff SUBJECT_SAMPLE_FACTORS 2460 TFA-T31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T31.wiff SUBJECT_SAMPLE_FACTORS 2463 TFA-T32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T32.wiff SUBJECT_SAMPLE_FACTORS 2878 TFA-T33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T33.wiff SUBJECT_SAMPLE_FACTORS 2879 TFA-T34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T34.wiff SUBJECT_SAMPLE_FACTORS 2883 TFA-T35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T35.wiff SUBJECT_SAMPLE_FACTORS 2386 TFA-T36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T36.wiff SUBJECT_SAMPLE_FACTORS 2743 TFA-T37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T37.wiff SUBJECT_SAMPLE_FACTORS 2747 TFA-T38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T38.wiff SUBJECT_SAMPLE_FACTORS 2899 TFA-T39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T39.wiff SUBJECT_SAMPLE_FACTORS 2900 TFA-T40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T40.wiff SUBJECT_SAMPLE_FACTORS 3029 TFA-T41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T41.wiff SUBJECT_SAMPLE_FACTORS 3030 TFA-T42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T42.wiff SUBJECT_SAMPLE_FACTORS 2738 TFA-T43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T43.wiff SUBJECT_SAMPLE_FACTORS 2741 TFA-T44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T44.wiff SUBJECT_SAMPLE_FACTORS 2847 TFA-T45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T45.wiff SUBJECT_SAMPLE_FACTORS 2852 TFA-T46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T46.wiff SUBJECT_SAMPLE_FACTORS 2854 TFA-T47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T47.wiff SUBJECT_SAMPLE_FACTORS 3024 TFA-T48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T48.wiff SUBJECT_SAMPLE_FACTORS 2385 TFA-T49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T49.wiff SUBJECT_SAMPLE_FACTORS 3102 TFA-T50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T50.wiff SUBJECT_SAMPLE_FACTORS 3104 TFA-T51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T51.wiff SUBJECT_SAMPLE_FACTORS 2744 TFA-T52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T52.wiff SUBJECT_SAMPLE_FACTORS 2745 TFA-T53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T53.wiff SUBJECT_SAMPLE_FACTORS 2844 TFA-T54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T54.wiff SUBJECT_SAMPLE_FACTORS 2845 TFA-T55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T55.wiff SUBJECT_SAMPLE_FACTORS 2846 TFA-T56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=TFA-T56.wiff SUBJECT_SAMPLE_FACTORS 2440 EicoT1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT1.wiff SUBJECT_SAMPLE_FACTORS 2443 EicoT2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT2.wiff SUBJECT_SAMPLE_FACTORS 2538 EicoT3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT3.wiff SUBJECT_SAMPLE_FACTORS 2547 EicoT4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT4.wiff SUBJECT_SAMPLE_FACTORS 3181 EicoT5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT5.wiff SUBJECT_SAMPLE_FACTORS 3183 EicoT6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT6.wiff SUBJECT_SAMPLE_FACTORS 2444 EicoT7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT7.wiff SUBJECT_SAMPLE_FACTORS 2445 EicoT8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT8.wiff SUBJECT_SAMPLE_FACTORS 2446 EicoT9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT9.wiff SUBJECT_SAMPLE_FACTORS 2336 EicoT10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT10.wiff SUBJECT_SAMPLE_FACTORS 2850 EicoT11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT11.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoT12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT12.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoT13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT13.wiff SUBJECT_SAMPLE_FACTORS 3099 EicoT14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT14.wiff SUBJECT_SAMPLE_FACTORS 2448 EicoT15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT15.wiff SUBJECT_SAMPLE_FACTORS 2449 EicoT16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT16.wiff SUBJECT_SAMPLE_FACTORS 2450 EicoT17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT17.wiff SUBJECT_SAMPLE_FACTORS 2901 EicoT18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT18.wiff SUBJECT_SAMPLE_FACTORS 2903 EicoT19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT19.wiff SUBJECT_SAMPLE_FACTORS 3020 EicoT20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT20.wiff SUBJECT_SAMPLE_FACTORS 3021 EicoT21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT21.wiff SUBJECT_SAMPLE_FACTORS 2451 EicoT22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT22.wiff SUBJECT_SAMPLE_FACTORS 2453 EicoT23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT23.wiff SUBJECT_SAMPLE_FACTORS 2454 EicoT24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT24.wiff SUBJECT_SAMPLE_FACTORS 2884 EicoT25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT25.wiff SUBJECT_SAMPLE_FACTORS 2885 EicoT26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT26.wiff SUBJECT_SAMPLE_FACTORS 2271 EicoT27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT27.wiff SUBJECT_SAMPLE_FACTORS 2282 EicoT28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT28.wiff SUBJECT_SAMPLE_FACTORS 2344 EicoT29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT29.wiff SUBJECT_SAMPLE_FACTORS 2458 EicoT30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT30.wiff SUBJECT_SAMPLE_FACTORS 2460 EicoT31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT31.wiff SUBJECT_SAMPLE_FACTORS 2463 EicoT32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT32.wiff SUBJECT_SAMPLE_FACTORS 2878 EicoT33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT33.wiff SUBJECT_SAMPLE_FACTORS 2879 EicoT34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT34.wiff SUBJECT_SAMPLE_FACTORS 2883 EicoT35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT35.wiff SUBJECT_SAMPLE_FACTORS 2386 EicoT36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT36.wiff SUBJECT_SAMPLE_FACTORS 2743 EicoT37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT37.wiff SUBJECT_SAMPLE_FACTORS 2747 EicoT38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT38.wiff SUBJECT_SAMPLE_FACTORS 2899 EicoT39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT39.wiff SUBJECT_SAMPLE_FACTORS 2900 EicoT40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT40.wiff SUBJECT_SAMPLE_FACTORS 3029 EicoT41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT41.wiff SUBJECT_SAMPLE_FACTORS 3030 EicoT42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT42.wiff SUBJECT_SAMPLE_FACTORS 2738 EicoT43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT43.wiff SUBJECT_SAMPLE_FACTORS 2741 EicoT44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT44.wiff SUBJECT_SAMPLE_FACTORS 2847 EicoT45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT45.wiff SUBJECT_SAMPLE_FACTORS 2852 EicoT46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT46.wiff SUBJECT_SAMPLE_FACTORS 2854 EicoT47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT47.wiff SUBJECT_SAMPLE_FACTORS 3024 EicoT48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT48.wiff SUBJECT_SAMPLE_FACTORS 2385 EicoT49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT49.wiff SUBJECT_SAMPLE_FACTORS 3102 EicoT50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT50.wiff SUBJECT_SAMPLE_FACTORS 3104 EicoT51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT51.wiff SUBJECT_SAMPLE_FACTORS 2744 EicoT52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT52.wiff SUBJECT_SAMPLE_FACTORS 2745 EicoT53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT53.wiff SUBJECT_SAMPLE_FACTORS 2844 EicoT54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT54.wiff SUBJECT_SAMPLE_FACTORS 2845 EicoT55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT55.wiff SUBJECT_SAMPLE_FACTORS 2846 EicoT56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon RAW_FILE_NAME=EicoT56.wiff SUBJECT_SAMPLE_FACTORS 2538 TFA-P1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P1.wiff SUBJECT_SAMPLE_FACTORS 2547 TFA-P2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P2.wiff SUBJECT_SAMPLE_FACTORS 2442 TFA-P3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P3.wiff SUBJECT_SAMPLE_FACTORS 2440 TFA-P4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P4.wiff SUBJECT_SAMPLE_FACTORS 3183 TFA-P5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P5.wiff SUBJECT_SAMPLE_FACTORS 3181 TFA-P6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P6.wiff SUBJECT_SAMPLE_FACTORS 3190 TFA-P7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P7.wiff SUBJECT_SAMPLE_FACTORS 2165 TFA-P8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P8.wiff SUBJECT_SAMPLE_FACTORS 2167 TFA-P9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P9.wiff SUBJECT_SAMPLE_FACTORS 2168 TFA-P10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P10.wiff SUBJECT_SAMPLE_FACTORS 2333 TFA-P11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P11.wiff SUBJECT_SAMPLE_FACTORS 2444 TFA-P12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P12.wiff SUBJECT_SAMPLE_FACTORS 2445 TFA-P13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P13.wiff SUBJECT_SAMPLE_FACTORS 2853 TFA-P14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P14.wiff SUBJECT_SAMPLE_FACTORS 2264 TFA-P15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P15.wiff SUBJECT_SAMPLE_FACTORS 2267 TFA-P16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P16.wiff SUBJECT_SAMPLE_FACTORS 2265 TFA-P17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P17.wiff SUBJECT_SAMPLE_FACTORS 2448 TFA-P18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P18.wiff SUBJECT_SAMPLE_FACTORS 2449 TFA-P19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P19.wiff SUBJECT_SAMPLE_FACTORS 2450 TFA-P20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P20.wiff SUBJECT_SAMPLE_FACTORS 3020 TFA-P21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P21.wiff SUBJECT_SAMPLE_FACTORS 2170 TFA-P22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P22.wiff SUBJECT_SAMPLE_FACTORS 2169 TFA-P23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P23.wiff SUBJECT_SAMPLE_FACTORS 2271 TFA-P24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P24.wiff SUBJECT_SAMPLE_FACTORS 2451 TFA-P25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P25.wiff SUBJECT_SAMPLE_FACTORS 2453 TFA-P26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P26.wiff SUBJECT_SAMPLE_FACTORS 2284 TFA-P27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P27.wiff SUBJECT_SAMPLE_FACTORS 2282 TFA-P28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P28.wiff SUBJECT_SAMPLE_FACTORS 2344 TFA-P29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P29.wiff SUBJECT_SAMPLE_FACTORS 2458 TFA-P30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P30.wiff SUBJECT_SAMPLE_FACTORS 2352 TFA-P31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P31.wiff SUBJECT_SAMPLE_FACTORS 2460 TFA-P32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P32.wiff SUBJECT_SAMPLE_FACTORS 2879 TFA-P33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P33.wiff SUBJECT_SAMPLE_FACTORS 2883 TFA-P34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P34.wiff SUBJECT_SAMPLE_FACTORS 2463 TFA-P35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P35.wiff SUBJECT_SAMPLE_FACTORS 2171 TFA-P36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P36.wiff SUBJECT_SAMPLE_FACTORS 2174 TFA-P37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P37.wiff SUBJECT_SAMPLE_FACTORS 2175 TFA-P38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P38.wiff SUBJECT_SAMPLE_FACTORS 2386 TFA-P39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P39.wiff SUBJECT_SAMPLE_FACTORS 2387 TFA-P40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P40.wiff SUBJECT_SAMPLE_FACTORS 2900 TFA-P41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P41.wiff SUBJECT_SAMPLE_FACTORS 2743 TFA-P42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P42.wiff SUBJECT_SAMPLE_FACTORS 2385 TFA-P43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P43.wiff SUBJECT_SAMPLE_FACTORS 2394 TFA-P44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P44.wiff SUBJECT_SAMPLE_FACTORS 2398 TFA-P45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P45.wiff SUBJECT_SAMPLE_FACTORS 2738 TFA-P46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P46.wiff SUBJECT_SAMPLE_FACTORS 2741 TFA-P47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P47.wiff SUBJECT_SAMPLE_FACTORS 2847 TFA-P48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P48.wiff SUBJECT_SAMPLE_FACTORS 2852 TFA-P49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P49.wiff SUBJECT_SAMPLE_FACTORS 2177 TFA-P50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P50.wiff SUBJECT_SAMPLE_FACTORS 2180 TFA-P51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P51.wiff SUBJECT_SAMPLE_FACTORS 2384 TFA-P52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P52.wiff SUBJECT_SAMPLE_FACTORS 2389 TFA-P53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P53.wiff SUBJECT_SAMPLE_FACTORS 2391 TFA-P54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P54.wiff SUBJECT_SAMPLE_FACTORS 2744 TFA-P55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P55.wiff SUBJECT_SAMPLE_FACTORS 2745 TFA-P56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma RAW_FILE_NAME=TFA-P56.wiff SUBJECT_SAMPLE_FACTORS 2538 EicoP1 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP1.wiff SUBJECT_SAMPLE_FACTORS 2547 EicoP2 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP2.wiff SUBJECT_SAMPLE_FACTORS 2442 EicoP3 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP3.wiff SUBJECT_SAMPLE_FACTORS 2440 EicoP4 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP4.wiff SUBJECT_SAMPLE_FACTORS 3183 EicoP5 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP5.wiff SUBJECT_SAMPLE_FACTORS 3181 EicoP6 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP6.wiff SUBJECT_SAMPLE_FACTORS 3190 EicoP7 Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP7.wiff SUBJECT_SAMPLE_FACTORS 2165 EicoP8 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP8.wiff SUBJECT_SAMPLE_FACTORS 2167 EicoP9 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP9.wiff SUBJECT_SAMPLE_FACTORS 2168 EicoP10 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP10.wiff SUBJECT_SAMPLE_FACTORS 2333 EicoP11 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP11.wiff SUBJECT_SAMPLE_FACTORS 2444 EicoP12 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP12.wiff SUBJECT_SAMPLE_FACTORS 2445 EicoP13 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP13.wiff SUBJECT_SAMPLE_FACTORS 2853 EicoP14 Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP14.wiff SUBJECT_SAMPLE_FACTORS 2264 EicoP15 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP15.wiff SUBJECT_SAMPLE_FACTORS 2267 EicoP16 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP16.wiff SUBJECT_SAMPLE_FACTORS 2265 EicoP17 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP17.wiff SUBJECT_SAMPLE_FACTORS 2448 EicoP18 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP18.wiff SUBJECT_SAMPLE_FACTORS 2449 EicoP19 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP19.wiff SUBJECT_SAMPLE_FACTORS 2450 EicoP20 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP20.wiff SUBJECT_SAMPLE_FACTORS 3020 EicoP21 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP21.wiff SUBJECT_SAMPLE_FACTORS 2170 EicoP22 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP22.wiff SUBJECT_SAMPLE_FACTORS 2169 EicoP23 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP23.wiff SUBJECT_SAMPLE_FACTORS 2271 EicoP24 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP24.wiff SUBJECT_SAMPLE_FACTORS 2451 EicoP25 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP25.wiff SUBJECT_SAMPLE_FACTORS 2453 EicoP26 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP26.wiff SUBJECT_SAMPLE_FACTORS 2284 EicoP27 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP27.wiff SUBJECT_SAMPLE_FACTORS 2282 EicoP28 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP28.wiff SUBJECT_SAMPLE_FACTORS 2344 EicoP29 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP29.wiff SUBJECT_SAMPLE_FACTORS 2458 EicoP30 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP30.wiff SUBJECT_SAMPLE_FACTORS 2352 EicoP31 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP31.wiff SUBJECT_SAMPLE_FACTORS 2460 EicoP32 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP32.wiff SUBJECT_SAMPLE_FACTORS 2879 EicoP33 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP33.wiff SUBJECT_SAMPLE_FACTORS 2883 EicoP34 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP34.wiff SUBJECT_SAMPLE_FACTORS 2463 EicoP35 Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP35.wiff SUBJECT_SAMPLE_FACTORS 2171 EicoP36 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP36.wiff SUBJECT_SAMPLE_FACTORS 2174 EicoP37 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP37.wiff SUBJECT_SAMPLE_FACTORS 2175 EicoP38 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP38.wiff SUBJECT_SAMPLE_FACTORS 2386 EicoP39 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP39.wiff SUBJECT_SAMPLE_FACTORS 2387 EicoP40 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP40.wiff SUBJECT_SAMPLE_FACTORS 2900 EicoP41 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP41.wiff SUBJECT_SAMPLE_FACTORS 2743 EicoP42 Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP42.wiff SUBJECT_SAMPLE_FACTORS 2385 EicoP43 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP43.wiff SUBJECT_SAMPLE_FACTORS 2394 EicoP44 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP44.wiff SUBJECT_SAMPLE_FACTORS 2398 EicoP45 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP45.wiff SUBJECT_SAMPLE_FACTORS 2738 EicoP46 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP46.wiff SUBJECT_SAMPLE_FACTORS 2741 EicoP47 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP47.wiff SUBJECT_SAMPLE_FACTORS 2847 EicoP48 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP48.wiff SUBJECT_SAMPLE_FACTORS 2852 EicoP49 Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP49.wiff SUBJECT_SAMPLE_FACTORS 2177 EicoP50 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP50.wiff SUBJECT_SAMPLE_FACTORS 2180 EicoP51 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP51.wiff SUBJECT_SAMPLE_FACTORS 2384 EicoP52 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP52.wiff SUBJECT_SAMPLE_FACTORS 2389 EicoP53 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP53.wiff SUBJECT_SAMPLE_FACTORS 2391 EicoP54 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP54.wiff SUBJECT_SAMPLE_FACTORS 2744 EicoP55 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP55.wiff SUBJECT_SAMPLE_FACTORS 2745 EicoP56 Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma RAW_FILE_NAME=EicoP56.wiff #COLLECTION CO:COLLECTION_SUMMARY Animals were sacrificed by CO2 narcosis, and large intestines were excised, CO:COLLECTION_SUMMARY washed with ice-cold PBS, and laid flat on filter paper. Tumor-adjacent CO:COLLECTION_SUMMARY full-thickness colon segments were flash-frozen in liquid Nitrogen and stored at CO:COLLECTION_SUMMARY -80C until analysis. Blood was collected via cardiac puncture and put in lithium CO:COLLECTION_SUMMARY heparin tubes on ice. Samples were centrifuged at 2,000 g for 20 minutes, and CO:COLLECTION_SUMMARY supernatant (plasma) was collected and stored at -80C until analysis. CO:SAMPLE_TYPE Blood (Plasma) and Large Intestine #TREATMENT TR:TREATMENT_SUMMARY Rats were fed two doses of TP-252 equivalent to consuming 1.3 and 2.6 g/kg/day TR:TREATMENT_SUMMARY for LD TP-252 and HD TP-252, respectively. Alternatively, rats were also fed a TR:TREATMENT_SUMMARY diet containing 2% EPA-FFA in their diet (equivalent to 1.14 g/kg/day of EPA). TR:TREATMENT_SUMMARY In groups receiving naproxen, the dose of naproxen was 11.4 mg/kg/day, or TR:TREATMENT_SUMMARY roughly 4 mg/rat/day. These treatment groups were carried out for the 20 weeks, TR:TREATMENT_SUMMARY and then animals were sacrificed and tissue collected and analyzed. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Samples (0.85 ml) were spiked with 5 ng each (in 150 μl methanol) of SP:SAMPLEPREP_SUMMARY 15(S)-HETE-d8,14(15)-EpETrE-d11, Resolvin D2-d5, Leukotriene B4-d4, and SP:SAMPLEPREP_SUMMARY Prostaglandin E1-d4 as internal standards for recovery and quantitation and SP:SAMPLEPREP_SUMMARY mixed thoroughly. The samples were then extracted for PUFA metabolites using C18 SP:SAMPLEPREP_SUMMARY extraction columns as described earlier [1-4]. Briefly, the internal standard SP:SAMPLEPREP_SUMMARY spiked samples were applied to conditioned C18 cartridges, washed with 15% SP:SAMPLEPREP_SUMMARY methanol in water followed by hexane and dried under vacuum. The cartridges were SP:SAMPLEPREP_SUMMARY eluted with 0.5 ml methanol. The eluate was dried under a gentle stream of SP:SAMPLEPREP_SUMMARY nitrogen. The residue was redissolved in 50 μl methanol-25 mM aqueous ammonium SP:SAMPLEPREP_SUMMARY acetate (1:1) and subjected to LC-MS analysis. SP:SAMPLEPREP_PROTOCOL_FILENAME Methods of Eicosanoid Detection.pdf #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 (3μ, CH:CHROMATOGRAPHY_SUMMARY 2.1x150 mm) column. The mobile phase consisted of a gradient between A: CH:CHROMATOGRAPHY_SUMMARY methanol-water-acetonitrile (10:85:5 v/v) and B: methanol-water-acetonitrile CH:CHROMATOGRAPHY_SUMMARY (90:5:5 v/v), both containing 0.1% ammonium acetate. The gradient program with CH:CHROMATOGRAPHY_SUMMARY respect to the composition of B was as follows: 0-1 min, 50%; 1-8 min, 50-80%; CH:CHROMATOGRAPHY_SUMMARY 8-15 min, 80-95%; and 15-17 min, 95%. The flow rate was 0.2 ml/min. The HPLC CH:CHROMATOGRAPHY_SUMMARY eluate was directly introduced to ESI source of QTRAP5500 mass analyzer CH:CHROMATOGRAPHY_SUMMARY (ABSCIEX) in the negative ion mode with following conditions: Curtain gas: 35 CH:CHROMATOGRAPHY_SUMMARY psi, GS1: 35 psi, GS2: 65 psi, Temperature: 600 ˚C, Ion Spray Voltage: -1500 V, CH:CHROMATOGRAPHY_SUMMARY Collision gas: low, Declustering Potential: -60 V, and Entrance Potential: -7 V. CH:CHROMATOGRAPHY_SUMMARY The eluate was monitored by Multiple Reaction Monitoring method to detect unique CH:CHROMATOGRAPHY_SUMMARY molecular ion – daughter ion combinations for each of the lipid mediators CH:CHROMATOGRAPHY_SUMMARY using a scheduled MRM around the expected retention time for each compound. CH:CHROMATOGRAPHY_SUMMARY Optimized Collisional Energies (18 – 35 eV) and Collision Cell Exit Potentials CH:CHROMATOGRAPHY_SUMMARY (7 – 10 V) were used for each MRM transition. Spectra of each peak detected in CH:CHROMATOGRAPHY_SUMMARY the scheduled MRM were recorded using Enhanced Product Ion scan to confirm the CH:CHROMATOGRAPHY_SUMMARY structural identity. The data was collected using Analyst 1.6.2 software and the CH:CHROMATOGRAPHY_SUMMARY MRM transition chromatograms were quantitated by MultiQuant software (both from CH:CHROMATOGRAPHY_SUMMARY ABSCIEX). The internal standard signals in each chromatogram were used for CH:CHROMATOGRAPHY_SUMMARY normalization, recovery, as well as relative quantitation of each analyte. CH:CHROMATOGRAPHY_TYPE None (Direct infusion) CH:INSTRUMENT_NAME Prominence XR CH:COLUMN_NAME Luna C18 (3u, 2.1x150 mm) column CH:FLOW_RATE 0.2ml/min #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:INSTRUMENT_NAME ABI Sciex 5500 QTrap MS:INSTRUMENT_TYPE QTRAP MS:MS_TYPE ESI MS:ION_MODE NEGATIVE MS:MS_COMMENTS Mass spectra for each detected lipid metabolite were recorded using the enhanced MS:MS_COMMENTS production feature to verify the identity of the detected peak. Data were MS:MS_COMMENTS collected and quantified using Analyst 1.6.2 (SCIEX) and MultiQuant (SCIEX) MS:MS_COMMENTS software, respectively. Correction for recovery efficiencies and relative MS:MS_COMMENTS quantitation of each analyte were performed using signals from each chromatogram MS:MS_COMMENTS corresponding to the spiked-in internal standards. Under standardized conditions MS:MS_COMMENTS of liquid chromatography-mass spectrometry quantitation, the detection limits MS:MS_COMMENTS for the eicosanoids are 1–2 pg on the column and the limit of quantitation is MS:MS_COMMENTS 5 pg at a signal-to-noise ratio of 3. #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS ng/g tissue MS_METABOLITE_DATA_START Samples EicoT1 EicoT2 EicoT3 EicoT4 EicoT5 EicoT6 EicoT7 EicoT8 EicoT9 EicoT10 EicoT11 EicoT12 EicoT13 EicoT14 EicoT15 EicoT16 EicoT17 EicoT18 EicoT19 EicoT20 EicoT21 EicoT22 EicoT23 EicoT24 EicoT25 EicoT26 EicoT27 EicoT28 EicoT29 EicoT30 EicoT31 EicoT32 EicoT33 EicoT34 EicoT35 EicoT36 EicoT37 EicoT38 EicoT39 EicoT40 EicoT41 EicoT42 EicoT43 EicoT44 EicoT45 EicoT46 EicoT47 EicoT48 EicoT49 EicoT50 EicoT51 EicoT52 EicoT53 EicoT54 EicoT55 EicoT56 Factors Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon 13,14dhPGE1 2.421 0.883 1.214 1.649 3.184 1.112 1.967 2.351 2.661 4.983 0.633 1.378 1.857 0.566 0.984 1.817 1.045 3.871 0.947 0.497 0.609 5.137 0.582 0.862 1.230 1.553 13,14dh-15k-PGE1 1.940 2.867 4.185 4.616 5.983 3.038 4.270 2.806 1.317 6.128 1.399 5.942 2.322 2.805 2.405 2.095 1.919 3.206 1.472 1.779 1.075 2.256 2.037 2.658 2.249 1.547 1.812 2.872 2.254 0.453 1.861 0.623 0.991 1.619 1.633 2.771 2.551 1.637 1.249 0.712 0.632 0.852 D17-PGE1 PGE1 183.678 66.748 206.016 108.637 163.794 232.989 258.099 16.757 7.297 16.000 50.311 15.727 79.481 14.752 147.692 146.349 114.514 168.729 113.359 116.614 121.942 68.015 82.364 121.486 53.073 202.388 68.860 45.087 14.986 9.540 14.252 13.956 42.992 40.610 31.057 17.530 6.448 14.309 13.659 31.690 19.414 83.884 52.679 187.243 17.667 72.525 74.349 129.077 167.317 19.815 11.398 10.623 1.888 8.893 15(R)-PGE1 19.444 46.585 24.233 8.792 3.919 7.628 20.742 6.512 28.910 6.888 9.854 13.624 11.837 2.363 4.803 3.875 8.117 2.238 7.989 3.848 6.053 3.817 2.254 15-keto PGE1 0.936 1.125 1.836 3.490 2.477 1.253 1.290 0.898 2.338 0.999 2.217 Bicyclo PGE1 2.063 6.179 20.896 11.758 17.550 17.368 29.077 3.892 14.939 13.931 13.773 21.625 8.534 10.466 8.264 3.510 7.288 8.676 3.990 19.607 4.433 2.536 2.883 14.094 2.514 2.791 4.661 4.224 6.076 19(R)-hydroxy PGE1 2,3-dinor PGE1 PGE2 1875.040 2393.090 3561.858 3141.265 4703.833 2677.378 2756.055 1465.824 639.674 633.195 3400.772 950.073 4083.563 1194.619 1759.598 1355.810 774.372 792.158 44.391 1674.120 1975.000 908.602 964.810 581.466 994.667 581.351 634.191 587.372 1295.638 740.582 327.074 878.178 850.007 1605.663 1134.390 188.227 1192.255 689.017 231.180 344.491 569.962 700.220 167.478 871.405 611.997 922.745 220.253 652.771 706.190 1260.751 1287.408 877.566 564.397 460.595 88.547 324.990 15-keto PGE2 32.219 97.408 114.124 146.991 247.302 130.184 86.022 24.623 7.234 20.088 85.536 25.267 37.609 43.586 34.805 45.324 41.758 65.912 2.268 60.982 55.147 11.230 46.812 32.334 17.315 19.421 30.723 21.976 16.138 4.784 10.476 32.562 22.619 16.043 2.244 8.995 11.710 4.744 14.424 9.425 8.119 5.067 30.667 52.898 23.442 29.754 52.100 37.343 86.629 107.833 9.926 13.240 8.387 3.405 12.216 13,14dh-15k-PGE2 145.088 186.355 370.070 232.735 446.164 346.205 419.213 65.231 35.317 25.064 173.706 43.583 187.354 51.497 296.025 232.185 156.412 184.760 4.316 165.606 243.978 99.072 87.634 62.692 140.962 79.704 174.254 110.280 56.451 31.965 13.186 34.619 34.729 71.834 49.351 10.281 54.241 27.382 10.122 14.421 30.190 30.079 28.598 90.619 76.715 197.002 40.660 106.389 152.988 161.660 189.345 39.402 22.590 24.469 5.908 14.424 Bicyclo PGE2 13.215 21.261 41.639 32.182 44.581 23.600 58.211 4.563 3.286 1.345 34.797 6.300 24.482 2.312 11.781 12.543 41.365 12.766 0.928 19.010 8.611 8.520 11.483 8.159 4.620 15.567 8.152 3.836 1.193 3.795 8.669 5.497 0.725 2.585 1.418 2.859 3.171 4.842 10.342 4.999 4.321 10.724 8.075 5.218 2.021 3.131 1.562 PGA2 552.984 875.903 1085.115 1242.335 1678.129 842.251 1089.647 138.729 68.177 51.015 893.551 159.577 448.045 185.171 395.804 359.853 686.869 424.337 6.027 527.850 518.546 291.589 282.043 336.272 389.296 152.164 506.088 116.984 244.424 83.449 21.918 49.291 51.134 258.164 187.525 12.506 122.244 50.800 19.051 39.306 66.034 105.615 147.976 161.574 144.327 396.815 65.790 178.244 229.097 435.662 476.119 131.850 41.156 60.338 7.684 35.435 tetranor PGEM 0.497 0.432 0.331 0.440 1.437 0.484 0.405 0.528 0.481 0.744 0.395 0.637 0.688 0.734 0.781 0.431 0.745 1.017 0.514 0.558 0.716 1.485 0.431 0.497 0.272 0.315 0.537 0.497 0.485 0.392 0.241 0.410 0.405 0.405 0.353 0.574 0.523 0.393 0.786 0.444 0.980 1.033 0.222 0.661 0.502 0.281 0.392 0.797 0.355 0.319 PGE3 6.820 6.215 12.864 11.356 28.205 7.562 10.152 1.864 2.474 131.192 96.837 72.107 134.170 16.144 169.180 212.802 241.806 398.602 127.140 136.667 109.745 333.840 165.105 83.507 77.278 13.487 49.646 52.810 135.658 51.062 46.945 215.639 93.873 34.945 117.026 105.850 99.844 15.145 138.040 90.146 128.564 28.212 36.826 77.520 81.733 56.273 90.306 46.370 68.919 17.310 21.289 PGD2 3627.597 4069.674 4080.768 3912.282 6317.116 3986.568 4952.696 434.007 261.696 172.713 3024.784 899.383 1614.471 693.456 1842.116 2192.430 3139.806 2402.866 30.795 2249.442 2283.037 1620.525 1571.215 1496.542 1880.052 791.328 2598.025 892.938 1593.996 456.559 99.909 163.040 200.790 1532.921 1157.149 34.717 556.273 290.856 93.597 265.565 376.581 689.160 1315.680 1157.450 856.902 2261.584 460.286 1236.769 1487.741 2674.384 3043.166 693.529 198.115 295.568 36.573 206.962 PGJ2 493.159 762.720 883.443 1125.593 1380.745 656.883 893.884 92.931 45.823 29.558 708.382 127.257 285.197 133.087 303.062 305.036 580.219 361.734 5.180 435.781 435.957 247.692 245.267 283.183 325.557 126.266 446.013 101.674 187.078 57.667 12.412 29.517 31.672 202.598 134.226 7.511 83.157 35.379 13.242 28.868 47.220 79.350 125.653 136.483 111.932 324.885 55.651 146.570 193.790 372.913 404.985 96.049 28.840 41.783 4.920 25.673 D12-PGJ2 237.441 13.213 6.605 37.517 61.735 29.310 82.545 117.167 92.247 108.393 69.847 94.901 8.282 9.251 4.277 48.247 49.240 132.934 7.981 1.695 7.348 15d-D12,14-PGJ2 5.720 14.529 18.762 31.869 25.421 11.573 18.378 1.143 0.605 18.682 2.621 4.640 2.011 6.397 6.012 11.502 13.676 6.522 6.803 10.904 8.778 6.553 2.998 2.163 4.711 4.366 2.852 1.106 2.719 2.105 2.747 4.616 1.857 2.232 4.873 5.596 1.397 13,14dh-15k-PGD2 224.692 273.568 442.405 295.923 358.915 179.786 735.599 36.721 17.737 27.743 198.602 27.368 101.515 34.762 121.929 117.439 340.466 154.569 154.852 109.797 100.101 98.317 108.595 118.766 43.389 168.750 55.520 64.635 28.606 10.563 23.049 29.006 68.368 37.143 27.264 21.281 30.396 51.783 51.226 56.196 238.591 22.573 62.284 83.519 132.766 133.866 53.382 29.417 15.701 PGD3 8.083 20.467 24.902 31.521 54.838 30.411 20.270 4.316 19.759 4.890 9.960 6.545 53.639 42.341 120.405 112.735 122.698 69.712 174.373 190.379 111.083 75.618 60.054 411.774 84.110 64.263 45.568 27.254 39.906 51.146 40.287 71.644 54.819 49.300 52.709 210.926 22.864 32.494 67.757 52.195 36.438 43.676 9.963 15d-D12,14-PGJ3 20.613 22.342 20.266 15.012 12.309 3.806 PGF1a 4.481 2.437 7.858 4.533 7.644 5.506 6.099 4.755 2.505 2.278 7.272 1.704 11.004 3.859 4.826 6.143 2.399 6.881 3.624 6.927 4.996 5.465 2.468 5.554 2.430 7.885 3.394 4.281 3.320 3.119 4.751 5.787 5.647 4.395 4.696 4.760 1.260 1.119 2.404 4.254 3.055 2.335 6.982 2.471 3.028 6.834 5.564 2.837 2.929 1.942 1.382 1.079 PGF2a 160.766 171.657 247.735 319.138 361.355 239.330 308.913 180.312 93.141 107.984 446.571 97.040 346.586 124.908 147.368 147.158 84.406 148.187 4.297 91.969 177.719 82.508 116.227 73.145 112.958 48.799 137.897 72.262 138.934 100.383 75.720 116.256 125.079 188.820 122.723 34.240 123.970 96.228 38.645 38.504 84.312 91.020 12.720 79.561 66.884 161.668 40.426 46.633 90.951 149.690 141.499 114.508 60.869 57.027 36.851 41.356 15-keto PGF2a 95.258 130.690 217.229 153.397 270.005 172.979 174.247 68.901 31.228 31.987 168.606 46.455 199.343 58.029 128.145 97.232 58.175 76.163 2.057 94.279 125.652 51.745 49.480 31.854 67.555 36.132 58.274 45.653 56.732 33.289 15.738 39.252 43.724 77.218 54.202 8.147 58.720 29.945 10.891 15.934 30.417 30.645 10.408 52.238 45.500 74.897 18.212 44.580 60.369 86.120 93.047 41.118 23.882 22.414 5.209 18.166 13,14dh-15k-PGF2a 6.016 8.406 17.643 23.548 33.289 25.917 42.554 6.909 1.921 3.625 24.482 3.697 8.929 4.156 19.672 21.803 14.804 37.875 9.419 27.552 18.538 11.626 11.731 34.608 5.156 32.754 14.011 7.218 3.215 2.888 4.764 7.355 3.002 2.978 4.135 2.921 8.240 9.701 38.298 11.625 7.048 20.402 33.150 37.024 4.941 2.555 2.552 1.324 PGF3a 2.907 2.770 4.766 6.569 3.782 4.557 8.766 13.192 8.373 4.134 3.220 14.502 5.502 4.069 4.705 2.843 6.530 2.497 2.322 6.410 5.049 3.640 4.543 5.237 3.478 3.883 9.079 3.241 2.586 2.025 5.010 1.151 1.196 iPF-VI 1.513 2.542 2.147 1.006 3.711 0.723 1.808 0.835 0.536 0.531 6kPGF1a 191.426 125.559 72.723 69.677 13.985 9.447 76.063 13.570 6-keto PGE1 6,15-diketo PGFa 6.771 12.824 10.345 22.292 10.134 35.687 1.006 25.290 18.012 21.972 24.373 5.716 21.203 16.174 8.346 12.487 19.985 13.429 6.107 17.664 2.712 10.962 14.505 25.390 12.924 9.737 17.705 15.795 17.027 TXB2 164.102 353.927 514.944 316.322 136.120 45.984 55.796 626.051 87.069 519.458 78.172 194.476 173.719 93.176 124.082 8.243 118.771 221.827 155.750 65.241 85.099 125.722 72.330 119.370 76.091 170.654 77.552 104.161 191.206 110.726 15.155 55.875 57.338 80.116 16.913 97.572 59.977 19.902 99.349 125.244 166.717 16.433 11dh-TXB2 4.361 4.332 7.328 24.800 8.539 5.075 8.852 4.334 46.743 2.208 9.686 2.404 7.282 1.695 2.327 2.008 4.057 2.001 1.535 1.289 1.512 7.824 3.026 1.519 3.164 9.417 3.282 2.856 1.416 1.781 1.546 1.873 1.270 1.215 2.495 5.255 1.840 2,3-dinor TXB2 11dh-2,3-dinor TXB2 4.899 2.056 4.157 4.328 0.841 0.611 0.708 0.708 14.330 TXB3 1.511 2.266 2.536 13.157 18.962 15.708 21.108 6.305 16.961 19.287 54.959 23.296 25.903 17.540 14.434 81.995 21.687 12.901 10.891 0.985 1.831 2.877 14.833 4.916 2.439 11.965 7.212 3.073 9.547 12.185 12.726 5.228 12.248 8.173 41.032 4.598 2.235 14.472 7.742 7.300 13.162 1.903 4.987 2.486 11dh TXB3 2.924 6.701 3.980 4.048 9.430 4.561 7.893 1.294 0.681 7.930 1.172 1.374 2.400 4.234 5.276 3.169 1.894 7.929 3.717 0.952 2.088 0.680 LTB4 4.059 11.892 7.854 7.861 7.290 14.740 6.987 2.709 2.472 17.910 3.707 13.622 6.516 1.030 1.091 1.849 3.070 1.492 3.213 1.700 2.487 0.487 1.351 2.010 3.832 1.944 2.047 2.816 5.597 2.859 0.778 1.805 1.881 0.834 0.955 1.086 3.209 0.841 0.661 2.370 1.479 5.255 1.587 2.145 0.249 0.824 12-OxoLTB4 1.779 0.468 0.484 1.215 0.506 0.815 0.290 1.069 1.558 1.002 0.837 1.802 1.270 0.637 1.079 1.719 0.964 20-hydroxy LTB4 0.108 0.071 20-COOH LTB4 0.089 0.068 0.032 18-carboxy dinor LTB4 10.453 6.055 10.947 19.593 18.473 11.354 6.684 6.954 LTB5 0.528 1.008 2.129 0.615 2.444 0.289 0.954 1.435 0.863 6.797 2.568 4.065 3.977 0.475 1.309 1.940 0.969 2.682 2.748 0.238 0.394 0.341 5(S),6(S)-DiHETE 0.963 1.046 0.372 0.333 5(S),12(S)-DiHETE 2.639 6.085 2.212 2.137 4.016 11.112 3.296 4.020 1.160 1.537 3.897 2.770 3.375 2.177 1.551 1.596 0.842 1.646 1.925 1.719 0.741 2.178 0.617 1.058 2.376 0.750 0.919 0.341 0.821 1.373 3.082 0.784 1.218 5.978 4.697 0.691 0.695 1.172 0.867 0.757 0.380 0.765 1.588 0.763 1.102 1.342 1.206 1.631 1.759 0.317 0.908 5(S),15(S)-DiHETE 0.437 1.176 1.737 1.842 1.359 0.383 2.381 0.285 0.537 0.927 1.500 0.572 0.386 0.610 0.586 0.401 1.303 1.468 1.198 0.405 0.523 0.880 1.724 0.487 0.404 1.917 1.154 0.224 0.280 8(S),15(S)-DiHETE 1.758 3.786 5.313 2.486 2.589 3.337 1.053 1.804 1.185 1.122 1.538 1.538 0.908 1.570 1.666 1.134 0.530 1.127 1.001 1.043 1.540 1.305 1.046 1.322 0.686 5(S),15(S)-DiHEPE 3.511 3.421 4.908 13.770 16.187 3.073 5.799 4.136 0.882 1.605 15.727 2.815 5.525 1.472 5.021 1.663 4.227 8.332 1.723 1.799 9.972 14.879 6.684 5.985 4.683 16.125 5.605 4.047 2.711 1.213 2.932 6.139 2.000 3.195 1.974 1.782 5.730 0.993 1.098 2.094 6.364 1.284 2.295 4.100 5.156 0.951 1.790 0.699 9-HODE 938.930 660.998 607.719 518.793 156.329 186.714 296.143 448.318 3512.980 3876.273 758.303 733.493 766.473 1763.611 787.123 4050.329 589.937 462.405 374.127 439.884 561.560 520.731 546.440 201.270 543.238 418.993 544.108 306.664 673.842 369.552 1474.731 1210.566 257.272 565.420 250.748 548.580 366.299 97.361 210.908 13-HODE 4511.916 11135.674 6933.437 9321.018 10456.298 11105.600 9919.975 6110.768 5480.018 1715.088 10184.317 1845.013 7052.243 3123.880 3319.328 6068.308 23115.789 22794.409 5057.705 7360.252 6493.589 7125.944 15094.013 6163.345 6792.483 3740.730 33757.252 6254.636 5407.258 5234.955 2764.665 6018.620 4724.437 5951.584 5363.441 3983.522 5126.983 5278.068 2272.182 6300.298 4069.130 5125.498 2035.170 5168.347 7763.852 5469.969 8953.103 6604.760 2744.222 6890.663 3023.780 5232.458 3170.003 2120.087 1016.622 1924.068 9(S)-HOTrE 46.967 188.191 40.007 104.377 57.517 82.532 38.261 64.036 54.163 35.064 73.493 13.890 35.167 21.284 15.968 56.816 413.522 932.880 125.523 71.160 38.535 55.452 209.232 74.056 61.888 71.583 1264.570 96.489 41.421 65.586 18.554 50.640 53.359 47.396 45.269 88.222 67.989 52.214 34.816 106.688 45.550 42.273 42.219 34.167 82.726 42.167 149.054 43.480 27.833 58.438 25.884 46.601 30.010 34.308 16.646 25.244 13(S)-HOTrE 117.491 331.342 100.767 111.648 96.609 971.523 73.399 371.182 116.578 29.922 125.667 47.504 67.407 57.681 30.814 78.540 555.465 953.305 138.370 86.285 68.468 54.217 299.979 65.382 85.708 111.276 1217.779 151.172 33.580 78.172 26.994 68.195 123.430 76.428 49.335 77.936 58.765 81.506 57.462 174.081 77.695 78.591 39.714 64.648 94.783 68.326 173.226 73.265 27.625 94.350 37.733 124.948 61.097 32.707 24.018 61.627 13(S)-HOTrE(g) 16.493 28.875 43.094 28.290 10.622 12.344 17.763 72.703 152.452 15.902 23.919 13.008 13.528 29.415 9.905 108.547 14.433 22.628 20.593 11(R)-HEDE 51.718 117.743 163.034 217.592 212.658 139.708 299.904 43.487 44.469 22.379 168.605 18.865 129.879 44.544 55.539 94.780 256.966 151.956 14.954 185.009 115.604 94.798 172.469 75.389 93.854 43.238 199.756 51.579 84.694 38.519 50.051 59.997 39.948 68.173 49.570 11.300 35.557 31.651 13.553 29.114 40.378 47.262 5.072 66.789 83.110 71.346 37.854 46.871 43.361 60.023 37.279 46.862 23.265 19.129 3.461 10.755 15(S)-HEDE 10.687 18.054 23.860 35.583 30.158 28.360 40.275 12.012 8.517 5.730 31.705 6.425 26.920 9.454 8.425 10.297 34.704 23.418 5.518 24.663 12.590 18.394 33.915 16.374 11.408 7.712 28.153 9.227 20.931 7.729 7.245 10.946 9.386 12.594 11.469 3.272 8.588 7.334 4.861 7.318 12.543 10.018 9.362 14.608 9.384 9.353 6.819 5.406 6.985 5.534 12.150 6.057 4.838 1.186 3.937 8(S)-HETrE 72.214 44.767 131.166 101.594 62.458 120.694 52.339 27.435 18.545 22.581 127.583 26.781 76.944 36.264 18.927 43.776 70.452 38.097 9.732 104.969 36.552 128.023 136.709 93.135 37.445 27.401 55.712 60.594 80.385 25.325 33.005 35.855 47.501 56.961 51.557 26.081 51.844 26.533 23.031 29.395 60.520 54.528 7.245 32.969 52.828 22.928 29.104 49.258 26.352 32.271 29.954 39.106 36.103 35.591 7.549 16.344 5(S)-HETrE 0.784 3.058 2.270 4.196 2.505 4.034 2.773 1.480 0.899 4.105 1.010 2.477 1.037 0.985 1.306 3.923 6.361 0.806 1.940 0.625 3.005 3.632 3.665 3.031 1.240 14.236 3.163 2.722 0.976 0.892 1.152 0.990 1.648 1.636 1.301 1.687 0.837 0.711 3.025 3.204 1.473 0.335 1.028 1.734 1.170 1.300 1.970 1.068 1.530 2.092 1.978 1.222 0.795 0.314 0.868 5-HETE 511.908 655.037 1804.375 1708.099 1225.617 1880.130 2112.801 572.505 481.625 308.778 3340.661 535.006 1583.222 635.012 219.156 382.035 727.008 405.809 134.290 793.785 372.288 606.166 779.838 438.249 321.093 192.182 476.992 692.506 241.010 358.163 376.590 331.965 574.398 518.274 204.698 414.339 222.529 163.291 190.837 444.453 387.882 52.612 234.819 386.358 284.173 203.400 461.079 215.886 260.831 236.918 580.530 305.284 251.369 58.754 153.043 8-HETE 308.792 366.550 328.489 439.922 394.680 679.138 453.274 139.071 143.274 249.288 784.840 181.299 309.995 137.432 65.160 112.084 160.663 106.021 35.192 228.674 92.328 157.348 254.003 162.572 78.923 72.001 114.327 74.773 234.434 63.875 123.481 107.090 111.714 137.931 125.144 57.503 79.887 60.914 52.526 59.228 148.651 125.310 16.801 81.493 121.046 62.539 75.805 187.042 57.071 69.335 76.012 135.942 99.150 84.514 17.581 51.325 9-HETE 83.173 102.028 157.107 253.318 246.214 278.856 230.916 72.370 66.115 65.712 385.650 83.709 177.609 73.303 35.183 62.894 111.430 68.388 19.837 120.150 58.733 98.373 134.416 88.382 48.020 35.216 127.770 42.282 140.253 31.531 57.699 53.008 54.859 87.985 70.242 30.999 45.783 38.983 23.543 43.861 89.201 69.251 7.873 43.538 70.967 34.981 37.536 84.342 30.306 45.892 45.199 66.700 59.728 40.759 10.352 27.064 11-HETE 8116.597 13828.873 16858.887 17937.026 24830.454 19864.782 25185.254 8229.152 8049.360 6373.437 24777.698 6122.861 23035.131 6386.365 9593.989 12320.719 16094.317 8260.991 708.352 13604.013 11355.307 9055.400 11415.088 6476.242 9881.193 5970.936 11259.425 7172.180 10506.431 4338.514 5657.770 7644.838 5973.742 9714.269 7526.432 1342.495 6452.864 5811.450 2725.743 2651.908 5986.755 7383.433 732.283 8351.254 8079.401 8390.419 4349.973 8274.464 6555.821 10839.778 8392.269 6775.027 4026.487 4026.764 578.446 2712.042 12-HETE 1311.580 3205.259 1772.693 1804.016 1719.160 6338.294 3538.014 1645.670 1257.553 785.395 2696.668 1418.320 4115.201 1090.597 916.689 1096.934 727.654 501.834 583.392 1267.392 1086.295 554.643 934.619 605.072 737.194 1008.737 311.205 661.756 811.170 209.909 987.399 842.890 1081.086 509.879 821.665 1707.024 1653.954 439.728 469.844 125.296 687.250 691.927 39.149 659.897 531.561 219.368 532.916 1214.078 391.710 722.527 573.852 817.535 602.019 704.723 164.807 624.658 15-HETE 1613.512 2535.908 4063.143 3350.897 4384.314 5855.991 5710.632 2056.442 2002.149 1540.604 6790.984 1751.055 5634.986 1814.162 1883.968 2559.893 2466.174 1186.712 211.955 2426.772 2275.926 1803.946 1722.884 1313.875 1355.756 1096.322 1412.562 1482.406 2401.449 755.371 1332.980 1684.875 1495.736 1821.155 1965.107 430.537 1355.400 1268.269 618.926 410.614 1383.167 1627.383 138.597 1614.389 1480.037 1544.120 852.551 1796.715 1159.497 1799.376 1606.695 1517.511 1067.748 857.515 160.340 646.050 20-HETE 151.374 147.453 187.789 109.633 68.349 81.146 373.095 66.208 169.571 61.103 180.228 500.543 48.067 63.583 315.818 49.590 1463.083 60.580 82.452 60.011 95.436 134.920 87.847 65.616 23.004 58.214 82.779 104.468 42.191 9.158 30.183 tetranor 12-HETE 8.591 4.345 10.088 9.868 7.555 12.963 5.256 3.234 6.072 3.973 11.240 3.835 14.305 2.053 4.910 9.814 1.453 2.056 3.963 6.030 2.983 14.874 2.881 1.593 1.027 1.400 2.259 5.114 3.040 2.787 1.249 2.787 2.628 1.735 1.491 1.086 2.029 3.019 4.990 1.293 1.550 2.437 12(S)-HHTrE 1551.547 1963.997 2810.843 2493.586 5820.007 2250.186 3146.462 2458.420 1402.392 1641.120 7196.304 1704.888 5502.427 1777.719 1821.428 1525.832 1036.626 573.224 41.141 1152.366 1756.041 963.636 1556.081 736.572 1391.135 790.046 957.896 1018.678 2304.167 1688.718 703.106 1708.961 2029.238 3402.622 2112.106 380.060 1402.579 1576.209 686.739 590.716 1414.585 1466.509 96.877 1467.729 1031.005 1440.456 332.765 810.014 965.704 1410.469 1152.688 2278.499 1065.618 1174.585 262.428 836.529 5-HEPE 20.873 18.752 45.826 27.962 22.799 56.063 55.220 39.617 20.033 7.924 100.383 12.503 23.657 9.051 134.354 276.526 2531.296 8051.518 396.746 446.364 173.925 1977.844 2679.115 1672.889 468.802 527.776 22514.429 1121.873 796.168 553.932 127.609 242.924 214.260 591.481 358.226 887.427 1080.292 813.873 473.945 2839.110 1809.111 994.130 366.044 205.335 774.097 742.623 637.455 168.609 227.525 249.943 125.156 1662.130 292.129 320.466 82.237 205.642 8-HEPE 22.561 10.838 7.561 15.419 10.279 16.461 12.873 7.996 13.643 5.497 29.805 4.143 7.669 53.118 79.527 366.528 1248.643 137.472 180.831 61.565 461.807 962.282 586.634 163.973 288.763 3071.303 371.113 261.345 112.752 47.940 79.848 97.070 190.121 102.936 245.966 269.583 210.789 210.172 471.812 473.354 273.504 53.195 71.579 240.724 119.035 194.459 69.485 59.722 44.063 31.338 269.697 109.658 122.472 28.573 79.101 9-HEPE 7.926 6.262 14.432 7.878 8.598 7.223 5.152 28.453 51.914 322.525 863.473 81.017 124.502 31.225 345.556 724.849 386.855 116.825 159.403 1724.007 212.885 202.975 102.659 31.144 48.226 62.661 142.845 65.840 144.279 202.438 178.648 152.222 503.221 418.344 194.552 41.722 47.880 180.900 106.907 101.461 42.528 43.887 34.749 26.093 205.524 65.508 67.600 16.971 51.014 11-HEPE 114.691 152.975 202.369 211.874 354.176 205.891 185.505 120.386 45.120 35.318 214.515 26.186 80.605 24.435 1209.526 1485.871 3445.886 4856.138 416.246 2337.833 1568.848 5026.694 8425.649 3902.139 3038.925 2027.616 14167.142 3105.908 2608.094 1353.065 488.617 802.129 852.824 2391.867 1099.110 749.864 2372.110 1991.308 912.816 2653.039 2957.719 2506.585 287.122 1475.296 2696.151 3205.713 1047.313 704.849 1253.066 1048.137 687.897 2144.569 742.649 611.071 163.265 456.156 12-HEPE 59.124 106.837 61.317 67.952 60.193 200.381 90.718 87.609 102.661 18.533 97.534 41.396 63.389 18.785 689.025 835.660 1162.363 3077.424 1865.790 903.514 663.412 1539.224 3898.264 1544.211 1602.844 2024.563 6666.660 2032.264 794.411 413.520 333.535 455.279 887.714 729.115 561.101 2767.477 3012.415 1214.845 1037.653 1064.078 1658.013 1553.424 137.078 763.345 924.110 533.311 1040.385 599.066 429.001 494.956 300.539 1858.290 786.934 695.259 287.240 811.643 15(S)-HEPE 46.800 58.123 53.834 86.450 82.978 163.384 79.194 55.496 61.646 10.302 110.767 21.676 40.575 15.146 416.273 534.825 2161.619 4924.803 493.327 805.774 481.625 1734.538 3899.241 1533.911 950.228 1573.479 14623.653 1675.035 817.925 478.111 191.009 284.343 537.199 804.995 506.127 567.055 807.607 853.826 661.864 1692.521 1638.192 1250.372 188.004 555.207 934.604 798.647 732.872 370.457 322.085 313.295 219.905 1497.024 438.125 324.676 122.009 442.485 18-HEPE 66.126 26.440 40.316 71.741 68.714 69.044 48.576 35.425 25.266 12.631 110.189 20.737 30.481 10.075 267.564 337.611 955.435 1989.176 316.221 441.132 251.720 1853.678 2889.525 1784.018 711.341 602.816 5564.564 964.194 992.358 406.962 158.116 274.399 302.335 767.287 413.219 468.584 744.474 757.747 462.586 1140.660 1377.305 1036.738 121.982 297.288 733.468 635.360 420.658 241.993 273.668 239.794 207.070 1043.852 400.236 385.835 116.032 258.622 4-HDoHE 40.433 45.977 47.825 81.393 43.566 55.492 44.005 34.640 22.571 13.421 101.307 16.852 46.654 20.160 12.725 32.272 76.380 121.025 58.917 70.265 46.080 44.530 266.845 69.939 33.799 18.622 217.579 58.239 39.645 21.211 33.535 34.878 31.806 28.884 28.995 60.699 44.778 20.425 18.131 28.217 48.321 25.631 12.243 28.607 47.300 15.926 95.531 73.183 25.048 25.907 20.294 38.082 31.698 15.174 15.445 11.983 7-HDoHE 6.221 10.846 11.573 18.202 10.092 12.887 15.166 5.295 4.558 4.549 15.970 4.186 9.977 5.356 3.666 6.411 15.317 20.998 3.906 10.197 5.651 12.132 28.301 13.399 6.747 4.342 41.375 5.406 8.221 5.049 7.851 6.565 5.651 6.542 6.676 9.377 8.250 3.498 5.893 4.144 11.156 5.560 8.794 9.193 3.859 16.119 16.962 4.078 5.910 5.063 5.768 6.923 3.412 2.372 2.684 8-HDoHE 13.273 23.558 20.738 35.330 20.081 24.297 16.930 12.388 9.008 8.221 33.049 9.712 23.597 8.311 5.865 16.991 41.981 65.436 24.086 27.487 17.686 18.708 91.653 30.582 14.334 11.520 122.846 16.552 23.463 10.947 17.066 16.992 15.542 14.584 12.019 23.759 20.240 11.022 11.821 19.027 25.501 13.845 6.334 16.701 25.744 7.805 42.158 29.733 9.594 11.230 11.684 12.508 13.956 9.861 6.529 4.682 10-HDoHE 49.001 69.220 29.494 51.796 35.439 49.674 36.369 16.355 12.138 27.412 55.149 13.936 30.263 14.188 10.890 22.664 53.131 85.970 24.321 32.322 23.467 34.712 92.932 37.163 22.106 19.307 177.310 29.466 27.852 12.648 16.778 22.805 21.079 18.242 20.112 31.495 25.577 18.414 15.173 24.620 35.218 24.785 9.067 18.595 39.223 13.456 45.206 42.964 16.626 17.859 16.021 27.438 24.247 11.965 7.773 10.534 11-HDoHE 14.684 31.010 24.336 44.783 36.939 12.725 11.023 11.948 42.162 9.948 18.374 10.818 18.498 41.424 65.825 19.877 29.144 19.286 78.122 28.824 13.844 137.743 21.500 26.554 11.594 13.623 19.101 19.135 15.731 18.075 30.741 25.109 13.258 12.656 19.323 25.039 12.948 6.539 30.376 34.406 30.230 10.645 13.000 13.015 14.341 13.930 9.522 7.516 7.826 13-HDoHE 100.128 199.320 246.780 276.942 380.192 344.590 398.089 62.883 66.832 56.539 141.102 44.993 162.227 40.156 123.959 214.726 440.680 237.430 40.406 291.590 218.102 188.175 280.975 133.918 182.553 118.401 665.299 151.933 71.716 33.400 79.291 87.485 64.302 56.033 55.803 85.067 111.098 63.165 47.210 44.626 67.685 60.808 19.664 202.757 172.515 179.483 135.863 200.814 107.473 177.934 117.561 47.740 43.337 64.299 16.952 26.916 14-HDoHE 102.190 176.369 109.036 111.607 96.118 408.437 239.854 60.820 34.902 35.490 66.500 91.920 39.303 54.835 95.093 100.383 137.858 65.941 128.066 71.841 80.544 197.085 66.137 66.250 103.453 239.553 90.600 42.090 23.019 39.727 42.512 51.626 50.423 61.223 53.810 57.387 53.459 45.613 36.375 99.720 67.324 13.274 70.318 73.038 35.943 110.649 118.263 32.467 47.244 93.814 47.538 33.953 12.563 43.685 16-HDoHE 60.260 99.480 88.890 107.606 122.737 175.341 125.275 37.394 36.790 32.124 106.311 38.226 79.292 27.744 41.104 89.489 175.223 121.516 43.055 120.401 85.323 91.140 152.477 82.897 64.888 33.307 230.416 62.123 73.654 21.167 51.398 37.921 47.491 43.789 44.166 59.124 69.536 37.598 34.840 30.858 62.419 46.460 20.864 63.123 91.086 62.920 120.746 132.908 50.894 76.465 66.608 39.351 42.624 27.499 16.331 22.202 17-HDoHE 25.569 54.574 35.716 21.366 18.493 157.669 89.460 26.846 23.545 14.522 35.563 30.059 30.657 18.990 24.450 28.437 38.344 33.613 10.491 26.702 27.482 14.851 24.942 12.297 13.951 24.448 61.194 29.188 6.250 5.602 17.305 14.232 20.466 8.404 15.557 14.805 18.503 20.011 16.663 8.779 23.266 22.133 3.597 24.604 12.968 14.709 33.281 39.467 11.716 20.280 17.660 29.557 13.105 9.656 4.888 14.000 20-HDoHE 69.095 93.868 103.062 169.913 128.668 162.241 126.661 50.574 41.958 30.108 147.941 41.514 109.198 37.575 48.555 90.894 132.639 121.359 61.347 120.274 89.241 113.006 233.310 96.878 78.365 39.970 255.762 86.964 82.483 32.992 56.560 60.621 49.617 65.787 62.875 90.703 97.567 48.827 35.062 44.690 74.730 55.896 20.832 70.583 102.730 57.102 124.147 131.311 51.214 77.854 72.241 63.140 65.618 30.290 31.565 31.972 9(10)-EpOME 51.458 170.024 41.020 67.265 48.483 61.648 68.771 81.290 49.563 24.372 136.679 26.326 51.444 42.018 34.142 56.044 1025.445 1114.942 152.626 158.281 53.346 64.310 424.293 96.462 42.966 38.709 1016.329 54.863 56.329 90.779 35.077 63.216 85.822 46.672 40.730 75.900 35.757 44.940 30.349 113.897 62.661 61.510 82.357 48.296 196.354 47.433 275.551 67.001 40.639 68.619 38.926 58.101 46.411 44.367 21.490 29.706 12(13)-EpOME 23.293 74.847 18.063 31.953 24.698 26.820 32.224 38.961 24.662 14.795 70.053 13.752 20.592 21.118 17.236 27.424 524.985 629.362 76.527 73.992 24.572 27.589 198.600 19.443 18.719 536.221 28.264 47.791 17.326 30.541 48.305 21.847 20.317 38.616 17.844 21.251 15.267 56.291 30.920 33.599 42.756 25.794 106.907 24.330 144.503 33.020 22.205 27.333 24.614 21.536 11.747 14.921 5(6)-EpETrE 10.818 9.222 12.848 14.217 16.295 23.569 20.449 11.029 7.635 5.050 35.971 7.899 11.625 8.966 2.966 5.017 13.229 6.490 3.416 16.293 4.894 5.368 17.695 7.134 3.155 2.801 4.903 6.877 11.489 3.724 6.514 7.291 7.767 6.581 6.517 4.577 5.102 3.673 2.858 3.611 6.472 5.892 1.741 3.831 8.994 2.852 5.767 8.683 3.825 4.019 3.542 4.976 4.335 4.636 1.034 2.752 8(9)-EpETrE 8.186 7.418 16.511 8.966 1.631 2.750 5.075 11(12)-EpETrE 24.302 33.636 15.639 13.852 19.619 34.198 42.873 25.875 17.340 90.126 30.814 32.089 32.765 8.268 21.123 40.012 13.411 15.202 58.920 21.585 14.800 67.391 29.406 8.691 11.520 9.683 13.461 6.679 27.530 15.968 26.389 9.511 12.734 10.406 8.971 7.220 10.120 22.862 12.861 6.953 8.184 30.075 25.522 40.273 9.536 12.128 16.537 14.892 15.393 3.335 11.010 14(15)-EpETrE 15.078 12.298 12.225 15.085 15.214 22.384 15.462 11.004 6.506 39.136 11.827 17.816 11.574 7.244 15.384 9.376 4.453 25.084 7.122 5.721 21.543 10.445 4.086 3.154 8.246 2.646 9.175 8.296 11.971 4.848 4.448 3.158 3.557 4.221 3.907 9.101 5.491 2.176 5.990 11.946 7.368 14.634 3.465 7.248 4.639 7.459 4.025 1.518 3.818 8(9)-EpETE 0.683 3.875 7.326 4.656 2.851 0.682 7.014 9.591 10.154 1.018 2.476 14.583 1.482 1.593 1.212 1.883 1.516 0.948 1.462 1.237 2.013 4.170 6.215 2.745 1.249 4.301 0.877 3.874 0.877 0.878 1.505 2.069 0.769 11(12)-EpETE 1.348 42.234 104.910 12.231 24.112 109.650 78.751 31.716 205.391 38.316 42.474 16.566 6.540 10.529 16.502 31.200 45.624 38.757 30.794 97.226 72.813 39.878 10.194 34.247 15.964 39.234 15.325 18.278 10.719 14(15)-EpETE 7.844 7.777 9.778 6.306 19.719 14.003 9.091 4.167 4.947 30.024 10.622 8.598 10.002 2.809 3.657 4.982 22.173 4.310 10.450 4.571 12.983 35.209 17.421 3.295 44.633 4.717 6.348 4.358 2.765 2.853 6.760 6.108 4.639 2.965 3.992 2.669 8.817 4.224 5.162 3.158 5.947 4.612 4.658 5.573 2.630 17(18)-EpETE 1.244 0.654 0.878 1.000 0.657 1.999 4.947 5.050 25.005 84.910 6.564 13.315 3.405 39.253 62.781 43.440 6.803 9.712 136.449 7.989 16.866 5.622 3.039 4.372 8.529 10.519 4.679 7.517 10.864 10.946 7.020 20.926 28.870 20.255 2.827 4.960 17.860 9.282 10.610 4.495 4.188 4.005 4.603 12.172 6.773 6.681 1.832 5.572 7(8)-EpDPE 0.871 1.347 0.647 0.688 1.038 0.894 0.910 0.356 1.622 0.388 1.044 0.729 1.276 1.643 1.286 1.388 0.704 3.468 0.848 0.477 0.451 2.068 0.473 0.405 0.563 0.694 0.535 1.222 0.620 0.912 0.410 1.040 0.614 0.346 0.630 1.550 0.494 2.385 0.986 0.480 0.446 0.441 0.379 10(11)-EpDPE 3.695 4.784 1.529 2.142 1.683 4.758 2.376 2.947 1.614 1.180 5.191 2.358 4.833 2.336 1.429 3.543 7.818 4.155 3.248 4.438 4.588 2.585 10.531 2.822 2.142 1.678 10.523 1.125 2.426 1.634 2.416 2.434 3.020 1.069 1.821 3.622 2.715 1.342 1.504 2.866 2.589 2.623 1.864 3.261 4.666 1.001 10.280 5.020 2.177 1.659 2.016 1.323 2.737 1.901 1.177 0.724 13(14)-EpDPE 1.690 1.999 2.072 1.266 2.281 0.763 3.684 1.122 2.246 1.350 1.949 3.114 1.542 1.129 0.937 5.587 2.366 1.281 0.573 2.723 0.670 1.098 0.691 1.637 1.207 1.995 0.617 1.971 1.387 1.028 1.747 1.725 1.406 0.982 2.068 3.284 0.507 5.893 2.622 1.226 1.226 1.495 1.759 0.816 16(17)-EpDPE 1.347 1.803 0.972 1.495 0.950 1.432 1.104 0.492 1.887 0.655 1.192 0.613 2.662 2.418 1.855 2.339 1.490 1.099 6.442 1.522 3.618 0.533 0.335 1.051 1.334 1.543 1.673 0.877 0.549 1.097 1.039 0.475 1.012 2.089 0.616 3.601 1.786 0.726 0.915 0.661 0.913 0.434 19(20)-EpDPE 2.311 2.445 2.138 2.750 2.247 2.825 2.257 1.609 1.409 0.566 3.514 1.607 2.158 1.109 0.668 2.044 6.828 7.157 2.136 3.747 2.089 2.178 7.794 2.515 1.380 0.851 10.898 1.432 2.830 1.210 1.458 1.855 2.052 1.373 1.044 2.730 2.392 1.093 1.204 1.049 2.850 1.660 1.235 1.563 3.177 1.116 5.235 3.668 1.286 1.527 2.741 1.294 1.959 1.264 1.353 1.142 9,10-DiHOME 26.560 55.848 24.809 66.938 33.230 24.020 18.656 25.422 18.403 7.159 48.441 9.620 17.806 9.720 12.936 20.314 178.717 386.029 43.033 38.537 19.087 28.326 66.202 62.767 23.243 22.983 459.667 25.710 26.789 54.733 10.226 23.746 29.836 37.128 15.870 43.850 47.872 26.385 12.481 61.272 33.094 28.628 81.933 33.863 63.187 39.638 50.225 45.962 17.375 51.265 20.509 52.728 23.725 17.730 10.009 13.182 12,13-DiHOME 23.458 30.570 28.761 82.293 30.724 20.368 20.180 20.493 10.912 6.178 59.164 6.827 16.963 7.791 11.379 13.268 105.636 221.534 21.513 23.172 16.533 40.691 44.388 54.468 18.544 16.218 306.089 19.034 27.778 33.920 8.032 15.399 20.166 25.809 12.804 30.768 37.079 20.694 9.430 42.402 37.485 30.461 53.678 23.938 44.458 29.074 39.288 31.715 11.670 42.239 12.742 49.910 18.451 14.300 7.681 10.111 5,6-DiHETrE 0.570 0.868 1.750 1.649 1.676 3.879 4.671 1.278 1.149 1.464 5.881 1.576 1.648 1.507 0.636 2.050 1.287 1.064 0.453 0.814 1.037 0.517 0.679 0.791 1.371 0.353 0.747 1.138 0.497 1.436 0.354 0.848 0.695 0.421 0.435 1.392 1.218 0.637 0.425 0.314 0.598 0.492 0.916 0.642 0.960 8,9-DiHETrE 1.040 0.558 4.578 6.220 3.373 3.330 2.517 0.965 0.567 9.816 1.001 2.229 0.959 0.660 0.865 0.925 0.954 0.505 1.541 1.447 0.531 0.472 0.367 2.750 0.414 0.590 0.679 0.889 1.114 0.624 0.997 0.642 1.590 1.389 0.297 0.586 0.551 0.605 0.511 0.229 0.668 0.597 0.995 0.545 0.468 0.109 0.310 11,12-DiHETrE 11.861 6.394 42.194 73.827 37.547 34.770 20.166 7.486 6.156 5.201 77.039 10.092 21.166 9.750 5.075 6.211 11.429 4.289 1.242 13.254 6.029 14.447 7.434 13.091 4.980 3.580 4.071 2.688 20.241 5.702 5.000 6.096 7.575 12.513 7.441 3.192 7.455 4.151 2.062 2.488 13.709 13.810 1.361 3.948 5.177 4.710 1.158 4.315 2.159 4.580 3.363 9.760 4.964 3.524 1.360 1.773 14,15-DiHETrE 29.558 18.843 107.514 216.815 100.897 72.731 37.268 19.181 12.039 11.452 171.837 20.281 47.379 19.055 12.247 11.994 31.722 16.850 2.716 35.908 15.123 35.099 17.254 32.967 11.144 6.791 10.408 6.201 46.316 18.567 13.014 15.235 19.978 29.239 16.476 5.016 12.108 10.985 4.274 6.473 30.888 31.413 5.834 8.874 12.157 15.320 3.559 12.928 5.624 11.336 6.132 30.866 12.810 8.925 2.883 5.017 5,6-DiHETE(EPA) 0.835 1.253 1.339 2.973 1.149 1.127 0.400 3.893 1.036 1.152 1.163 0.508 1.413 0.628 1.750 1.044 0.816 0.436 0.245 0.705 0.252 0.444 0.761 0.682 19,20-DiHDoPE 0.958 0.764 1.399 3.424 5.462 1.644 1.210 0.681 0.521 2.438 0.468 1.291 0.885 0.971 5.559 3.716 1.007 3.831 1.558 2.575 8.990 3.364 1.842 1.408 6.768 1.172 2.375 1.196 1.150 1.074 1.247 1.968 1.322 1.336 1.208 1.041 0.794 1.267 2.247 1.688 0.635 1.222 3.826 1.115 1.750 1.673 0.519 1.565 0.816 1.620 0.956 1.367 0.518 0.618 9-OxoODE 538.664 1106.091 518.346 754.071 519.622 683.362 661.788 662.349 216.555 238.971 1223.230 239.431 429.130 424.128 240.205 566.260 5892.786 6210.859 1500.746 1213.397 290.667 618.705 1963.111 529.591 413.382 396.590 9639.595 540.449 639.636 491.161 248.367 582.933 803.875 375.315 514.469 577.121 519.456 610.325 276.041 784.473 413.284 585.771 326.554 475.139 971.129 329.216 1426.311 858.604 264.218 619.137 316.607 544.627 430.777 421.308 179.092 289.721 13-OxoODE 577.406 1593.451 517.701 968.562 997.954 1193.836 822.766 855.999 404.792 267.313 1424.435 273.751 400.346 468.438 276.591 743.797 7331.277 11450.749 1489.624 1366.282 599.126 714.114 4531.223 1058.211 872.575 438.446 17358.556 659.748 682.956 848.115 267.758 608.319 905.202 583.530 576.330 569.439 482.814 703.536 273.180 1200.070 652.542 670.625 393.742 603.411 1459.948 409.105 1633.619 839.999 274.292 778.048 461.063 541.538 443.948 374.353 184.104 306.844 9-OxoOTrE 11.965 51.304 8.738 22.112 4.292 13.245 9.343 18.220 7.779 6.054 19.674 8.149 6.727 8.227 6.498 21.090 369.904 599.431 58.649 31.646 14.415 12.144 124.733 17.835 10.059 13.621 892.839 19.240 11.158 27.154 5.802 17.123 13.754 13.370 11.440 22.522 13.634 20.209 9.518 33.388 13.170 12.730 12.396 9.920 27.151 11.090 46.782 15.410 7.850 21.999 9.306 10.635 7.623 11.800 5.020 9.303 15-OxoEDE 5.136 3.738 3.212 2.113 2.805 8.986 2.532 16.546 16.600 3.548 3.665 1.163 19.878 21.912 1.080 3.757 2.515 2.811 2.359 3.013 0.798 1.832 5-oxoETE 12-OxoETE 15-OxoETE 21.825 25.045 27.516 59.086 69.047 67.661 55.070 25.170 16.886 13.693 78.281 25.809 34.659 23.271 9.629 15.298 13.406 37.529 13.478 15.628 38.515 14.461 10.896 12.942 23.961 8.858 9.368 12.729 26.389 16.167 17.167 7.827 10.200 9.558 11.457 11.951 19.579 12.122 9.464 12.722 19.960 21.331 18.875 9.189 14.686 23.365 14.200 16.622 14.564 6.966 13.829 LXA4 1.044 5.248 4.918 2.224 1.448 0.880 0.390 7.462 0.707 2.285 1.058 0.264 2.692 1.032 0.388 0.555 2.277 0.698 0.323 0.415 0.736 0.345 0.179 15-epi LXA4 0.301 0.335 0.685 0.746 0.542 0.280 0.255 0.582 0.182 0.622 0.297 0.366 0.450 0.220 0.282 0.386 0.130 0.349 0.336 0.314 0.453 15-oxo LXA4 0.591 1.163 1.674 1.668 1.577 1.570 0.992 0.903 0.750 0.605 0.623 0.473 0.342 1.004 0.496 0.465 0.685 LXA5 0.175 1.810 0.216 1.267 0.889 6.721 2.805 1.623 5.974 0.959 0.420 1.542 1.235 1.052 0.862 0.247 1.618 0.361 2.271 0.727 1.103 1.270 3.690 1.713 0.948 LXB4 0.415 2.876 0.865 5.021 0.924 2.096 1.177 6.269 0.462 RvD1 1.612 3.113 6.441 3.505 2.956 1.835 3.146 4.324 2.277 1.304 1.584 1.895 RvD2 3.762 4.864 6.371 12.233 5.594 4.755 5.134 12.295 2.441 1.044 3.363 3.266 2.110 4.128 6.514 3.776 18.534 1.875 1.914 3.410 2.233 4.827 3.041 2.093 RvD3 AT-RvD3 1.171 1.490 1.678 1.057 1.355 0.740 0.521 0.690 0.485 RvD4 0.533 0.550 RvD5 RvD6 (4,17-DiHDoHE) 0.890 1.130 1.042 1.042 0.890 1.624 0.451 0.807 0.521 0.702 0.493 1.151 0.643 2.723 0.907 0.651 1.027 0.796 0.344 0.501 0.589 0.584 0.619 0.892 0.558 0.381 0.561 0.501 8-oxoRvD1 17-oxoRvD1 RvD5(n-3DPA) (7,17-DiHDoPE) RvE1 0.500 RvE2 0.094 0.202 0.547 2.294 3.005 2.619 0.623 0.492 3.035 1.976 0.871 0.765 0.162 0.225 0.240 1.121 0.546 0.492 1.473 0.831 0.532 0.910 1.689 0.553 0.255 0.538 0.950 0.614 0.228 0.278 0.159 1.698 0.553 RvE3 3.431 3.750 1.856 2.058 2.230 10.184 1.804 0.702 PD1 0.549 AT-PD1 PD1(n-3, DPA) 101.454 99.788 67.036 67.966 106.769 90.900 80.206 66.065 98.334 53.459 72.588 133.312 105.419 66.031 78.006 189.074 120.525 165.265 55.458 94.022 33.777 63.932 83.362 10S,17S-DiHDoHE 8.433 3.917 9.333 2.590 22-OH-PD1 Maresin1 0.719 0.519 0.538 7(S)-Maresin1 0.536 0.720 1.090 MaR1(n-3DPA) 1.519 1.221 2.543 0.517 2.298 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name KEGG ID PubChem ID quantified m/z 13,14dhPGE1 161273 356 13,14dh-15k-PGE1 16061097 372 D17-PGE1 5283114 352 PGE1 C04741 7312 354 15(R)-PGE1 5283056 354 15-keto PGE1 C04654 5280710 352 Bicyclo PGE1 5283055 338 19(R)-hydroxy PGE1 5283115 370 2,3-dinor PGE1 16061101 326 PGE2 C00584 5280360 352 15-keto PGE2 C04707 5280719 350 13,14dh-15k-PGE2 C04671 5280711 352 Bicyclo PGE2 137699601 334 PGA2 C05953 5280880 334 tetranor PGEM 161468 328 PGE3 C06439 5280937 350 PGD2 C00696 448457 352 PGJ2 C05957 5280884 334 D12-PGJ2 C05958 5280885 334 15d-D12,14-PGJ2 C14717 5311211 316 13,14dh-15k-PGD2 5283036 352 PGD3 C13802 5282260 350 15d-D12,14-PGJ3 PGF1a C06475 5280939 356 PGF2a C00639 5280363 354 15-keto PGF2a C05960 5280887 352 13,14dh-15k-PGF2a 5283039 354 PGF3a C06476 5280940 352 iPF-VI 42607309 354 6kPGF1a C05961 5280888 370 6-keto PGE1 C05962 5280889 368 6,15-diketo PGFa 174013 370 TXB2 C05963 5283137 370 11dh-TXB2 C05964 5280891 368 2,3-dinor TXB2 5283138 342 11dh-2,3-dinor TXB2 35024530 340 TXB3 5283140 368 11dh TXB3 16061115 366 LTB4 C02165 5280492 336 12-OxoLTB4 5283130 334 20-hydroxy LTB4 C04853 5280745 352 20-COOH LTB4 C05950 5280877 366 18-carboxy dinor LTB4 6438938 338 LTB5 5283125 334 5(S),6(S)-DiHETE 5283161 336 5(S),12(S)-DiHETE 9997164 336 5(S),15(S)-DiHETE 5283158 336 8(S),15(S)-DiHETE 5283183 336 5(S),15(S)-DiHEPE 5283180 368 9-HODE 5283944 296 13-HODE C14762 6443013 296 9(S)-HOTrE C16326 6439873 294 13(S)-HOTrE C16316 16061072 294 13(S)-HOTrE(g) 5282971 294 11(R)-HEDE 16061090 324 15(S)-HEDE 5282705 324 8(S)-HETrE 5283148 322 5(S)-HETrE 5283143 322 5-HETE C04805 5280733 320 8-HETE C14776 5283154 320 9-HETE 14123398 320 11-HETE 5312982 320 12-HETE C14777 5283155 320 15-HETE 9966861 320 20-HETE C14748 5283157 320 tetranor 12-HETE 5282970 266 12(S)-HHTrE 5283141 280 5-HEPE 6439678 318 8-HEPE 16061128 318 9-HEPE 16061129 318 11-HEPE 16061130 318 12-HEPE 10041593 318 15(S)-HEPE 16061131 318 18-HEPE 16061132 318 4-HDoHE 14429109 344 7-HDoHE 16061142 344 8-HDoHE 11976798 344 10-HDoHE 11537494 344 11-HDoHE 11631564 344 13-HDoHE 11559259 344 14-HDoHE 11566378 344 16-HDoHE 11595378 344 17-HDoHE 6439179 344 20-HDoHE 16061143 344 9(10)-EpOME C14825 6246154 296 12(13)-EpOME C14826 5356421 296 5(6)-EpETrE C14768 5283202 320 8(9)-EpETrE C14769 5283203 320 11(12)-EpETrE C14770 5283204 320 14(15)-EpETrE C14771 5283205 320 8(9)-EpETE 16061085 318 11(12)-EpETE 16061087 318 14(15)-EpETE 16061088 318 17(18)-EpETE C13843 16061089 318 7(8)-EpDPE 11653103 344 10(11)-EpDPE 11638767 344 13(14)-EpDPE 11674605 344 16(17)-EpDPE 14392758 344 19(20)-EpDPE 11631565 344 9,10-DiHOME 5282958 314 12,13-DiHOME 5282961 314 5,6-DiHETrE C14772 5283142 338 8,9-DiHETrE C14773 5283144 338 11,12-DiHETrE C14774 5283146 338 14,15-DiHETrE C14775 5283147 338 5,6-DiHETE(EPA) 14429105 336 19,20-DiHDoPE 16061148 362 9-OxoODE 5283011 294 13-OxoODE C14765 6446027 294 9-OxoOTrE 11380794 292 15-OxoEDE 5283013 322 5-oxoETE C14732 5283159 318 12-OxoETE C14807 5283162 318 15-OxoETE C04577 5280701 318 LXA4 C06314 5280914 352 15-epi LXA4 9841438 352 15-oxo LXA4 5221886 350 LXA5 6439927 350 LXB4 C06315 5280915 352 RvD1 16126783 376 RvD2 53477504 376 RvD3 53477497 376 AT-RvD3 44251573 376 RvD4 53477505 376 RvD5 25073195 360 RvD6 (4,17-DiHDoHE) 25073193 360 8-oxoRvD1 53477507 374 17-oxoRvD1 44576257 374 RvD5(n-3DPA) (7,17-DiHDoPE) RvE1 C18171 10473088 350 RvE2 C18173 16061125 334 RvE3 56848721 334 PD1 16042541 360 AT-PD1 24778497 360 PD1(n-3, DPA) 86288884 362 10S,17S-DiHDoHE 11667655 360 22-OH-PD1 Maresin1 60201795 360 7(S)-Maresin1 42607314 360 MaR1(n-3DPA) 132472313 362 METABOLITES_END #END